ArticleSurgery today2025
Outcome of hepatectomy after systemic therapy for hepatocellular carcinoma: a Japanese multicenter study.
Article in Surgery today, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Postoperative liver function trajectories and risk factors after hepatectomy for hepatocellular carcinoma.Surgery today · 2026Article
- Spatiotemporal dynamics of the tumor microenvironment in hepatocellular carcinoma during combination immunotherapy.Hepatology communications · 2026Article
- Impact of laparoscopic repeat hepatectomy on the outcomes of recurrent hepatocellular carcinoma.Surgery today · 2026Article
- Comparison of Anatomical and Non-Anatomical Resection in Low Microvascular Invasion Risk Solitary Hepatocellular Carcinoma ≤ 5 cm.Annals of gastroenterological surgery · 2026Article
- Surgical strategy for repeated metastasectomy for advanced colorectal cancer with synchronous liver metastases.Surgery today · 2026Article
- Article
- Survival impact and recurrence prediction using oncologic resectability classification in hepatocellular carcinoma following hepatic resection: a Japanese multi-center study.International journal of clinical oncology · 2025Article
- A randomized comparative study evaluating water-jet with CUSA for parenchymal dissection in living-donor liver procurement: WORLD trial.International journal of surgery protocols · 2025Article
- Feasibility of non-routine abdominal drainage for minimally invasive liver surgery: study protocol for a multicenter randomized controlled clinical trial.International journal of surgery protocols · 2025Article
- Surgical treatment for hepatocellular carcinoma in era of multidisciplinary strategies.International journal of clinical oncology · 2025Review
- Hilar Cholangiocarcinoma with Para-Aortic Lymph Node Metastasis Treated with Chemoimmunotherapy and Conversion Surgery: A Case Report.Surgical case reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
background and purposeIn recent years, new systemic therapies have been developed for hepatocellular carcinoma (HCC). The aim of this study was to evaluate the prognosis of patients with unresectable HCC treated with R0 hepatectomy after systemic therapy.
methodsData from 27 patients who underwent hepatectomy for HCC after systemic therapy at six facilities were analyzed retrospectively. Cancer-specific survival (CSS) and recurrence-free survival (RFS) after hepatectomy were investigated using Kaplan-Meier curves. We examined the prognostic value of the oncological criteria of resectability for HCC reported by the Japanese Expert Consensus 2023.
resultsR0 resection was performed in 24 of the 27 patients. Using the Response Evaluation Criteria in Solid Tumors, 0 patient had a complete response, 16 had a partial response, 6 had stable disease, and 2 had progressive disease. Median CSS was not evaluated, but the median RFS was 17.8 months. Patients with resectable and borderline resectable (BR) 1 cancers had a better prognosis than those with BR2 cancers. The group whose oncological criteria were improved by systemic therapy had a lower recurrence rate than the group whose oncological criteria were maintained, but no difference was observed in CSS.
conclusionsThe findings of this study suggest that hepatectomy after systemic therapy may improve the prognosis of HCC patients.
Indexed as
Identifiers
39192138What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.